Form 4 Filing for Agios Pharmaceuticals, Inc.

This filing details transactions by Foster-Cheek Kaye I, a director at Agios Pharmaceuticals, Inc., on June 18, 2026. The transactions include the acquisition of 2,927 restricted stock units (RSUs) and 14,950 stock options, with vesting dates in 2027. Additionally, 2,816 RSUs were disposed of, and there was an acquisition of 2,816 shares of common stock. Following these transactions, Foster-Cheek Kaye I holds 2,200 shares of common stock indirectly through the Foster Family Revocable Trust and directly owns 10,284 shares of common stock. The RSUs represent a contingent right to receive one share of common stock upon vesting, with details on vesting schedules provided in footnotes.